• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Picard Issues Statement on Intraday Stock Price

    10/24/25 3:07:57 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care
    Get the next $PMI alert in real time by email

    TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company's operations or financial condition, that would account for the recent volatility in its stock price.

    The Company remains focused on executing its strategic and operational priorities and will continue to comply with all disclosure obligations under applicable securities laws.

    For additional information about Picard Medical, please visit www.picardmedical.com or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.

    About Picard Medical and SynCardia

    Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com

    Forward-Looking Statements

    This release may contain forward-looking statements within the meaning of federal securities laws. Such statements are based on current expectations and are subject to risks and uncertainties that may cause actual results to differ materially. The Company undertakes no obligation to update or revise any forward-looking statements.

    Contact:

    Investors

    Eric Ribner

    Managing Director

    LifeSci Advisors LLC

    [email protected]

    Picard Medical, Inc./SynCardia Systems, LLC

    [email protected]

    General/Media

    Brittany Lanza

    [email protected]



    Primary Logo

    Get the next $PMI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sindex Ssi Lending, Llc claimed ownership of 7,943,585 shares (SEC Form 3)

    3 - Picard Medical, Inc. (0002030617) (Issuer)

    11/13/25 4:15:36 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    SEC Filings

    View All

    Picard Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    12/9/25 4:15:26 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    12/4/25 8:00:58 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    12/3/25 4:05:27 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Picard Celebrates Patient Living a World-Record of Over Eight Years with the SynCardia Total Artificial Heart

    -Picard Medical / SynCardia Systems LLC mark historic milestone as a patient reaches 2,900 days of continuous support with the SynCardia Total Artificial Heart -- the longest timeframe in the world ever recorded- TUCSON, Ariz., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, proudly marks a new milestone in the field of mechanical circulatory support with a patient living over eight years or 2,900 days with a SynCardia™ Total Artificial Heart (STAH), the longest timeframe that a patient has ever lived on

    12/9/25 4:05:00 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany

    TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th through 6th, 2025 in Frankfurt, Germany. Details of the presentation are below: Date: Saturday, December 6, 2025Time: 13:00 – 13:45 CETSession: Durable Mechanical Circulatory SupportLocation: Red Ro

    12/3/25 4:05:00 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025

    TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will present in vitro data on the fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025), held in Vienna, Austria from December 1st through 4th, 2025. Details of the presentation are below: Date: Thursday, December 4, 2025Time: 14:05 Central European Time (CET). Session: Mini Oral Session 3: Hemocompatibility and Hea

    11/26/25 7:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care